(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate

We are (7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate CAS:179688-53-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate
CAS.NO:179688-53-0
Synonyms:6-Acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one
3,4-dihydro-4-oxo-6-acetyloxy-7-methoxy-quinazoline
Molecular Formula:C11H10N2O4
Molecular Weight:234.20800
 
Physical and Chemical Properties:
Density:1.39
Melting point:26ºC
Boiling point:452.391ºC
Flash point:227.398ºC
Index of Refraction:1.612
 
Specification:
Appearance:Off-white to grey to brownish grey powder
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Gefitinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate


Related News: The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.106266-04-0 The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months.1,1-dicloropinacolina CAS:22591-21-5 Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.

Related Products
Product Name
Methylaminoacetaldehyde dimethyl acetal View Details
2,4-Difluorobenzoic acid View Details
3-[(1S)-1-(dimethylamino)ethyl]phenol View Details
6-Chloro-5-fluoroindolin-2-one manufacturer 4-bromo-9-methyl-9-phenyl-9H-fluorene manufacturer nervonic acid manufacturer 2-Cyanobenzyl bromide manufacturer 5-Bromo-2-Hydroxy-3-Picoline manufacturer